June 6, 2026

GLP-1 Drugs Turn Out to Have a Lot More to Say About Cancer

6 discoveries · 15 good-news notes · 580 articles read

The common thread

Today had one of those rare combinations where news from completely different corners of the science world ended up pointing at the same place. Start with the cancer story, because it is genuinely extraordinary: a drug called daraxonrasib just doubled survival time for people with advanced pancreatic cancer, taking median survival from 6.7 months to 13.2 months in a 500-person trial [451]. Pancreatic cancer has been the stubborn holdout in oncology, one of the very few cancers where survival rates have barely budged for decades. This is the first real crack in that wall. And in almost the same breath, a study of more than 110,000 women found that the medications behind Ozempic and Wegovy reduced breast cancer risk by about 30% [11]. The GLP-1 drugs keep turning up in places nobody expected them. Then there was cobalt. Cobalt, of all things. Scientists have studied this metal for 40 years and thought they understood it completely. A team using advanced spectroscopy at a Berlin synchrotron facility just found a dense network of hidden quantum states running through cobalt's electron structure that nobody had ever detected, states that remain stable at room temperature and can be switched with magnetism [17]. It is a little vertiginous to realize that one of the most familiar metals in the world was hiding an entire layer of quantum complexity we simply could not see until now. On the same day, University of Chicago researchers published a theoretical method for creating powerful quantum states using the simplest possible setup, just small adjustments to atom energy levels inside an optical cavity [1]. Both discoveries point at the same emerging picture: quantum physics is becoming less exotic and more practical, moving from expensive specialized hardware toward tools that work in ordinary lab conditions. The brain multitasking finding from Georgetown deserves a moment [80]. The conventional wisdom, repeated in every productivity seminar for the past 30 years, is that human multitasking is an illusion and that the brain can only rapidly switch between tasks. That turns out to be incomplete. After tracking participants through more than 30,000 image-sorting trials over several weeks, researchers watched something happen in brain scans: the neural circuitry for a well-learned task physically migrated out of the prefrontal cortex, the bottlenecked executive region, and into the temporal cortex, freeing up the frontal networks to handle something new in parallel. The brain does not eliminate the bottleneck; it routes around it by building a dedicated highway. This also explains, as a side note, why compulsive behaviors are so hard to think your way out of. Once an automated skill settles into the temporal cortex, it is no longer easily accessible to conscious intervention. On the good-news front, Europe quietly had a remarkable year for rivers. In 2025, 603 river barriers were demolished across the continent, the most ever removed in a single year, reconnecting about 2,300 miles of waterways [451]. Sweden led with 173 removals. Along the River Dee in Wales, sea lamprey nests were already appearing in places they had not been seen in decades after one weir came out. And for the first time in history, wind and solar generated more electricity globally than gas did in April 2026, accounting for 22% of the world's electricity versus 20% from gas [458]. That is a milestone, not a fluke; renewable capacity has been growing fast enough that this was a trend catching up to a long-obvious trajectory, not a one-month spike. One practical implication worth carrying into your week: the sleep research out of the University of Arizona tracked 23,000 adults for nine years and found that sleeping fewer than seven hours, napping frequently during the day, and persistent insomnia each independently predict more white matter lesions in the brain, the kind of tissue damage tied to dementia risk [74]. The good news embedded in that finding is that all three of those behaviors are modifiable. If the research tells us that protecting seven to nine hours of uninterrupted sleep does measurable things to the physical structure of the brain, that is a concrete invitation, not a vague wellness suggestion.

Natural Sci.Good News

Two separate research teams published findings about GLP-1 drugs on the same day, and together they paint a more complex picture of these medications than most people carry. First: a Stanford Medicine study found that roughly 10% of people carry genetic variants that make them far less responsive to Ozempic and...

Read the full story
Life SciencesTechnologyHuman Stories

Georgetown University researchers tracked participants through more than 30,000 image-sorting trials over five to ten weeks and watched what happened to their brains before and after they became experts at the task. Using fMRI and EEG, they found that expertise caused a physical migration: neural processing shifted...

Read the full story
Life SciencesPsychologyHuman Stories

A University of Arizona team analyzed brain MRI scans from more than 23,000 adults who had answered sleep questionnaires up to nine years earlier, and found that three specific sleep habits predicted significantly more white matter lesions: sleeping fewer than seven hours per night, frequent daytime napping, and...

Read the full story
Natural Sci.TechnologyGood News

A University of Cambridge spinout called DIOSynVax tested a vaccine in 39 healthy human volunteers that was designed not to target a single coronavirus strain but to target features shared across the entire Sarbeco coronavirus family, which includes SARS-CoV-2, SARS, and multiple bat coronaviruses with pandemic...

Read the full story
Good News

A 500-person clinical trial of daraxonrasib, a drug targeting the key protein that drives pancreatic cancer, found that it doubled median survival time for patients with advanced disease, from 6.7 months to 13.2 months. It also produced fewer side effects than chemotherapy [451].

Read the full story
Social Sci.TechnologyHuman Stories

In the first encyclical of his papacy, Pope Leo XIV published "Magnifica humanitas," arguing that AI is not intrinsically immoral but that its adoption needs to slow to build moral guardrails, establish social safety nets for displaced workers, and create democratic processes to keep technology development under...

Read the full story

The discoveries, in full

Natural Sci. Good News

GLP-1 Drugs Turn Out to Have a Lot More to Say About Cancer

Two separate research teams published findings about GLP-1 drugs on the same day, and together they paint a more complex picture of these medications than most people carry.

First: a Stanford Medicine study found that roughly 10% of people carry genetic variants that make them far less responsive to Ozempic and similar diabetes drugs, a phenomenon the researchers call "GLP-1 resistance." These individuals actually produce higher-than-normal levels of GLP-1 naturally, but the hormone does not work effectively in their bodies, and they were significantly less likely to reach blood sugar targets after six months of treatment [6]. Second and separately: a University of Pennsylvania study of more than 110,000 women found that those on GLP-1 medications had about 30% lower likelihood of developing breast cancer [11]. Clinical trials are now being planned to test that finding directly.

What each field noticed
ScienceDaily

Scientists discover why ozempic may not work for some people

The Stanford research shows that not all patients are equal when facing these drugs, which has direct implications for precision medicine in diabetes care. If doctors could screen for these genetic variants in advance, they could route patients toward the treatment most likely to help them rather than waiting six months to discover a drug is not working [6]. The researchers explicitly frame this as a step toward personalized diabetes care, and they note that the roughly 10% of the population carrying these variants represents a substantial number of people currently on a medication that is not benefiting them.

Read the story
ScienceDaily

Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk

The Penn research is observational, which means it cannot yet prove cause and effect, and the researchers are careful about that. But a 30% reduction in breast cancer incidence across 110,000 women is a signal strong enough to justify the prospective clinical trial they are now planning. The leading hypothesis is that GLP-1 drugs reduce cancer risk at least partly through weight loss, but researchers are not certain that weight alone explains the effect [11]. The coverage missed almost entirely the question of what these two findings together suggest about population-level screening: if one in ten people is genetically resistant to GLP-1 drugs for diabetes while a separate cohort benefits from significant cancer risk reduction, the optimization questions around who gets prescribed these drugs become considerably more complicated.

Read the story
Life Sciences Technology Human Stories

The Brain Can Learn to Actually Multitask, Through Neurological Migration

Georgetown University researchers tracked participants through more than 30,000 image-sorting trials over five to ten weeks and watched what happened to their brains before and after they became experts at the task.

Using fMRI and EEG, they found that expertise caused a physical migration: neural processing shifted from the prefrontal cortex, where deliberate, bottlenecked executive thought happens, into the temporal cortex, a region associated with memory and object recognition [80]. Once that shift happened, the frontal networks were genuinely free to handle a second demanding task simultaneously. The brain does not multitask by switching fast; it multitasks by permanently reassigning an automated skill to a different neural address.

What each field noticed
Neuroscience News

True Brain Multitasking Is Possible

The Georgetown team's key finding demolishes a 30-year assumption. Multitasking is not an illusion; it is a developmental achievement that requires building dedicated, parallel neural circuits through sustained practice. The paper also explains why compulsive behaviors are so difficult to override through willpower: once a behavior becomes automated and migrates to the temporal cortex, it is no longer easily accessible to conscious thought [80]. This has immediate implications for addiction therapy, which has often tried to address compulsive behavior through cognitive strategies that cannot reach the circuits where the behavior now lives.

Read the story
MIT Technology Review

Are AI chatbots making us lose control of our brains?

Psychologist Gloria Mark has spent 30 years measuring attention spans in real environments. In 2003 the average worker focused on one task for two and a half minutes before switching. By 2012 it was 75 seconds. By 2020 it was 47 seconds [328]. Mark argues that AI assistants are accelerating this fragmentation, and that the stress response from constant attention-switching shows up measurably in heart rate data. The implication is that technology may be actively preventing the kind of sustained practice that builds the neural circuits the Georgetown study describes.

Read the story
Big Think

The trick that offloads intrusive thoughts so your brain can actually work

David Epstein and Gloria Mark both describe the "brain residue" problem: every time you switch tasks, a residue of the previous task lingers on your cognitive whiteboard, making it harder to focus on the next thing [579]. The Zeigarnik effect compounds this because unfinished tasks leave persistent imprints. Batching tasks and protecting extended focus time are the practical interventions that have the strongest evidence behind them, which aligns directly with what the Georgetown study suggests the brain needs to build its migration circuits. The coverage missed the question of what sustained practice with AI assistance might do to this neurological architecture: if AI handles the demanding parts of complex tasks, does it prevent humans from building the automated circuits that enable genuine parallel processing later?

Read the story
Life Sciences Psychology Human Stories

Sleep Protects the Physical Structure of the Brain, and That Structure Can Be Shaped

A University of Arizona team analyzed brain MRI scans from more than 23,000 adults who had answered sleep questionnaires up to nine years earlier, and found that three specific sleep habits predicted significantly more white matter lesions: sleeping fewer than seven hours per night, frequent daytime napping, and persistent difficulty falling or staying asleep [74].

White matter lesions are associated with cognitive decline and elevated Alzheimer's risk. The study isolated these three behaviors independently, controlling for blood pressure, smoking, and physical inactivity, which makes the findings more actionable than the usual broad "sleep quality" correlations. Separately, a Geneva University Hospitals study trained 18 people with nightmare disorder to associate a new, positive dream narrative with a piano chord, then played that chord during REM sleep using a bone-conduction headband; nightmare frequency dropped significantly and the benefit lasted at three-month follow-up [151].

What each field noticed
Neuroscience News

Irregular Sleep Habits Linked to Increased Brain Tissue Damage

The Arizona study's strength is its dataset size and its longitudinal design: the sleep data came first, the brain scans came nine years later. This structure does not prove causation, but it substantially strengthens the case that specific sleep behaviors precede brain tissue changes rather than just coexisting with them. The finding that frequent daytime napping correlates with more lesions is notable because brief naps are often recommended for alertness; the study did not isolate nap duration or timing, which will be the focus of future research [74].

Read the story
Scientific American Mind

How Sleep Engineering Could Help Heal the Brain

The Geneva sleep engineering study shows that sleep is not just something that happens to us. Its architecture can be deliberately shaped. The technique used in the nightmare study, delivering a cue during REM sleep that the waking brain has already associated with a positive narrative, is being adapted for PTSD, where nightmare disorder is a major barrier to recovery [151]. The approach is non-pharmacological, uses consumer-grade hardware, and has shown durable benefits.

Read the story
Psyche

How to navigate your menopause

The Monash University neuropsychologists link hormonal change directly to sleep disruption, noting that 60 to 80 percent of women experience hot flashes and night sweats during the menopause transition that fragment sleep, and that the resulting sleep changes carry their own cognitive and mood consequences [121]. The pathway from hormonal change to brain health runs partly through disrupted sleep architecture, which makes the Arizona study's findings particularly relevant to a population whose sleep disruption is often under-treated. The coverage did not address the obvious policy question: if irregular sleep is driving measurable brain damage in 23,000 people tracked over nine years, what workplace and social structures are producing that irregularity, and what interventions would actually help at scale?

Read the story
Natural Sci. Technology Good News

An AI-Designed Vaccine That Aims at Entire Virus Families Passes Its First Human Trial

A University of Cambridge spinout called DIOSynVax tested a vaccine in 39 healthy human volunteers that was designed not to target a single coronavirus strain but to target features shared across the entire Sarbeco coronavirus family, which includes SARS-CoV-2, SARS, and multiple bat coronaviruses with pandemic potential.

The vaccine was created entirely by AI: machine learning analyzed genetic surveillance data from coronaviruses worldwide, identified conserved features across the whole virus group, and combined them into a single "super-antigen." In the Phase I trial, the vaccine was safe and generated immune responses not just against SARS and COVID-19 but also against related bat viruses that have never infected humans [12]. It was the first time a vaccine whose active ingredient was designed entirely through computer simulation was tested in people.

What each field noticed
ScienceDaily

AI-designed universal coronavirus vaccine passes first human trial

The scientific significance is layered. It is a Phase I result, which means it establishes safety but not efficacy. But the immune responses against bat viruses with pandemic potential are notable because those viruses have never been tested against any human immune system before. If a single vaccine can train the immune system against multiple coronaviruses simultaneously, including ones we have not yet encountered, the economics and logistics of pandemic preparedness change substantially [12].

Read the story
MIT Technology Review

Rehumanizing global health care with agentic AI

The MIT coverage does not address the Cambridge vaccine specifically, but it traces the broader pattern of AI taking over complex design and administrative tasks in healthcare, freeing human clinicians for care that requires human judgment [335]. The Cambridge vaccine sits at the most ambitious end of that continuum: AI not just assisting with known biology but synthesizing a novel biological entity from scratch.

Read the story
Positive News

What went right this week

The good news roundup covered a separate pancreatic cancer breakthrough in the same issue [451], framing it as part of the same week's run of genuine medical progress. The universal vaccine appeared alongside it as evidence that the pace of medical research has meaningfully accelerated. The coverage did not engage seriously with the regulatory implications of approving a vaccine whose active ingredient was designed by an algorithm, which is a genuinely novel question for every drug safety agency in the world.

Read the story
Good News

A Drug Finally Cracks Pancreatic Cancer's Wall

A 500-person clinical trial of daraxonrasib, a drug targeting the key protein that drives pancreatic cancer, found that it doubled median survival time for patients with advanced disease, from 6.7 months to 13.2 months.

It also produced fewer side effects than chemotherapy [451]. Pancreatic cancer has a five-year survival rate below 15% and has not seen meaningful progress against advanced disease in decades. Daraxonrasib works by shutting down a protein that pancreatic tumors have long been considered "addicted" to, but which was previously considered essentially undruggable. Regulators are now evaluating whether to approve it as a standard treatment.

What each field noticed
Positive News

What went right this week: the good news that matters

The Positive News account quoted a Cancer Research UK scientist calling pancreatic cancer "one of those really stubborn cancers which has lagged behind." The framing was calibrated rather than triumphalist: this doubles survival time for advanced disease, which means it buys months, not decades. But it is a real crack in a wall that has resisted every previous attempt [451].

Read the story
The Optimist Daily

Podcast Transcript June 5th: Pancreatic cancer cracked, hepatitis B cleared, and wild mice who run for joy

The Optimist Daily covered this trial alongside a hepatitis B drug that cleared the virus from one in five patients entirely, not suppressed: cleared [503]. The host described an oncologist crying at her desk when she read the trial results, which captures accurately what it means when decades of stagnation in a lethal disease suddenly break. Nothing in the medical science or life sciences categories covered this story, which is unusual for a 500-person Phase III trial result presented at the ASCO Annual Meeting. The field's context for why the target protein was considered undruggable and what changed technically to make daraxonrasib possible went largely unexplained.

Social Sci. Technology Human Stories

The Pope Weighs In on AI and What Makes Human Work Human

In the first encyclical of his papacy, Pope Leo XIV published "Magnifica humanitas," arguing that AI is not intrinsically immoral but that its adoption needs to slow to build moral guardrails, establish social safety nets for displaced workers, and create democratic processes to keep technology development under public rather than oligarchic control [172].

The document also argued that "intelligence" is a human property machines cannot possess, and made a historic formal apology for the Church's previous defense of slavery. The encyclical was shaped with input from Anthropic co-founder Chris Olah, among other AI experts. On the same day, a separate Vox piece reported on a growing "AI successionist" movement whose members believe AI should eventually replace humanity and that trying to align AI with human values is the wrong goal [168].

What each field noticed
Vox Future Perfect

The pope takes on AI

The encyclical's most significant framing is economic and democratic rather than theological. Leo XIV focused on who gets displaced, who makes the decisions, and whether there will be democratic accountability for those decisions [172]. Its release included AI experts and industry leaders at the presentation, which is unusual for a papal document and signals how seriously the Vatican takes this as a practical rather than merely metaphysical question.

Read the story
Vox Future Perfect

The people who actually want AI to replace humanity

The successionist movement, as described by Vox, was represented at a closed-door symposium that included people from Anthropic, Google DeepMind, and think tanks shaping US government AI policy [168]. These are not fringe voices. Their argument is that since humans cannot remain unchanged across centuries of technological change, we should embrace the kind of change that transforms us most radically, including the possibility of extinction and replacement by something more capable. The article's author describes this as a crisis of human self-valuation: value is not dispensed from a cosmic vantage point; it is always value to someone.

Read the story
MIT Technology Review

Are AI chatbots making us lose control of our brains?

Gloria Mark's attention research is directly relevant here: if AI tools are already measurably degrading human cognitive independence by fragmenting attention and outsourcing deliberation, the encyclical's concern about human dignity is not abstract but physiological [328]. The question of what makes human work distinctively human has an empirical dimension that policy discussions rarely engage with.

Read the story
New Scientist

A golden age of maths is dawning and mathematicians are freaking out

The mathematics piece shows what AI displacement looks like from inside a profession. Senior mathematicians at major research conferences are quietly wondering whether to start certain research projects at all if AI will get there first [27]. The field is navigating, in compressed form, the same question the pope is raising: what is distinctively human about human intellectual work, and what happens when that distinctiveness erodes? The coverage missed the question of what historical precedents exist for institutions successfully slowing a major technology's adoption to allow social adjustment. The industrial revolution is the obvious comparison, and that adjustment took a century.

Read the story

Good news you might have missed

What went right this week: the good news that matters A drug called daraxonrasib doubled survival time for people with advanced pancreatic cancer in a 500-person trial, from 6.7 months to 13.2 months, the most meaningful progress against this disease in decades, with regulators now evaluating it for approval [451]. Positive News
What went right this week: the good news that matters Europe removed 603 river barriers in 2025, a record, reconnecting 2,300 miles of waterways; sea lamprey nests are already appearing on the River Dee in Wales where a single weir was recently taken down [451]. Positive News
What went right this week: life-changing inventions, plus more Wind and solar generated more electricity globally than gas did in April 2026 for the first time in history, 22% of the world's electricity versus 20% from gas, a milestone driven by sustained investment in renewables rather than a one-month anomaly [458]. Positive News
Podcast Transcript June 5th, 2026: Pancreatic cancer cracked, hepatitis B cleared, and wild mice who run for joy A new drug cleared hepatitis B from the body entirely in one out of five patients in a recent trial: not suppressed, cleared [503]. Hepatitis B chronically infects roughly 300 million people worldwide and had previously been considered manageable but not curable. The Optimist Daily
Podcast Transcript June 5th, 2026 Researchers placed exercise wheels in open fields and sand dunes, and wild mice, entirely unprompted and with no food reward, ran on them voluntarily for extended periods, suggesting that exercise motivation in mammals may be intrinsic rather than learned [503]. The Optimist Daily
Study Reverses Structural Autism Deficits in Brain Cells Japanese researchers using a chemogenetic technique restored shortened axon initial segments in autism mouse models to normal length, and watched sociability recover and repetitive behaviors drop sharply, the first demonstration that these specific structural neural deficits are fully reversible [81]. Neuroscience News
AI Detects Early Epilepsy Signs in EEG Data An AI system accurately identified a genetic epilepsy mutation from baseline EEG recordings with no seizures present, opening a path to earlier diagnosis in children and reducing the months families currently spend waiting for a seizure to occur during a monitoring session [78]. Neuroscience News
Flu Drugs May Slow Cognitive Decline A Northwestern University team found that sialidase inhibitors, commonly known as Tamiflu-class drugs, preserved protective sugar molecules in blood samples from HIV-positive patients, reducing inflammation, reversing signs of premature aging, and protecting memory circuits in preclinical models [77]. Neuroscience News
'Relentless Outreach': The State That Doesn't Give Up on Mentally Ill Residents California's CARE Court program connected one man who had cycled through homelessness, psychiatric crises, and jail for nearly two decades with steady outreach clinicians who simply kept showing up until he accepted help, demonstrating that persistent, non-coercive engagement works even for people with severe untreated psychosis [462]. Reasons to be Cheerful
Inside Germany's 'Schools Without Racism' Germany's Schule ohne Rassismus network, which asks at least 70% of a school's students, teachers, and staff to formally commit to opposing discrimination and practicing bystander intervention, now includes more than 5,000 schools and 2.5 million students, with the program operating in five additional European countries [467]. Reasons to be Cheerful
The blood cancer that became solvable Carvykti, a one-time CAR-T cell infusion for multiple myeloma, is producing durable long-term remissions in patients who had relapsed after multiple prior therapies, the first time this painful cancer has yielded to something resembling a cure rather than a cycle of treatment and relapse [269]. Works in Progress
Giant fire tornadoes could clean up oil spills faster with less pollution Texas A&M researchers showed that controlled fire whirls can burn crude oil nearly twice as fast as conventional methods while cutting soot emissions by 40% and consuming up to 95% of the oil, offering a practical new tool for preventing offshore spills from reaching sensitive marine habitats [4]. ScienceDaily
Veganism in Tanzania Vegan activists in Tanzania are running festivals and building community networks while pointing out that many traditional Tanzanian meals, beans, maize, cassava, bananas, and leafy greens, are already naturally plant-based, reframing veganism not as a Western import but as a return to foods people already know [392]. The Vegan Society
What went right this week: life-changing inventions, plus more Fathers in the US have cut paid work hours by an average of six per week since the pandemic while raising childcare and housework hours by more than four, a measurable generational shift in how men participate in family life that researchers describe as a genuine recalibration of contemporary fatherhood [458]. Positive News
What Could Go Right? Blue Marble Redux The Artemis II crew brought humanity deeper into space than any humans had gone in more than 50 years, carrying the first woman and first Black man beyond low-Earth orbit, and the mission's launch director was herself a woman, a visible marker of how much the institutions that build the future have changed [521]. The Progress Network

Everything we read today

Natural Sciences 61 articles
Life Sciences & Medicine 42 articles
STAT
Psychology & Behavioral Science 60 articles
Social Sciences 124 articles
The Conversation Articles
Technology & Innovation 49 articles
Futurism
Plant-Based & Vegan 94 articles
Solutions & Good News 124 articles
Good News Network
Sunny Skyz
Human Stories & Ideas 26 articles

Get this every morning.

One short, warm email with the day's real progress. Free, forever.